
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
The American Academy of Dermatology's new taskforce on bioterrorism is faring well enough to the point where the volunteersare already outnumbering the tasks.